Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Eli Lilly sales and marketing update

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Cancer The pharmas Lilly Oncology unit launched the PACE Continuous Innovation Indicators (CII) tool to measure progress against cancer. CII will initially …

    Published on 2/16/2015
  • Merck sales and marketing update

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Neurology Merck launched Belsomra suvorexant in the U.S. to treat adults with insomnia. The dual orexin receptor antagonist is available in 5, 10, 15 and …

    Published on 2/16/2015
  • Multiplicom sales and marketing update

    Multiplicom N.V., Niel, Belgium Business: Diagnostic Multiplicom began enrolling molecular diagnostic laboratories as part of an early access program for Clarigo Dx, a non-invasive prenatal diagnostic that detects fetal…

    Published on 2/16/2015
  • Premaitha Health sales and marketing update

    Premaitha Health plc (LSE:NIPT), Manchester, U.K. Business: Diagnostic Premaitha received CE Mark approval and launched its Iona non-invasive prenatal in vitro diagnostic in Europe to assess the risk of a fetus having …

    Published on 2/16/2015
  • UnitedHealth Group, University of Texas MD Anderson Cancer Center sales and marketing update

    UnitedHealth Group Inc. (NYSE:UNH), Minneapolis, Minn. University of Texas MD Anderson Cancer Center, Houston, Texas Business: Cancer The center and UnitedHealthcare launched a bundle payment model for head and neck …

    Published on 2/16/2015
  • Exact Sciences, CMS sales and marketing update

    Exact Sciences Corp. (NASDAQ:EXAS), Madison, Wis. Centers for Medicare & Medicaid Services, Baltimore, Md. Business: Diagnostic Exact Sciences said CMS updated its 2015 reimbursement rate for Exacts Cologuard colon …

    Published on 2/9/2015
  • Galderma sales and marketing update

    Galderma S.A., Lausanne, Switzerland Business: Dermatology Galderma launched Restylane Silk Injectable Gel with lidocaine for submucosal implantation for lip augmentation and dermal implantation for correction of …

    Published on 2/9/2015
  • GenomeDx Biosciences sales and marketing update

    GenomeDx Biosciences Inc., Vancouver, B.C. Business: Diagnostic GenomeDx said Medicare administrative contractor Palmetto GBA issued a positive coverage policy through its MolDX Program for GenomeDxs Decipher Prostate …

    Published on 2/9/2015
  • Gilead, Catamaran, Cigna Corp. sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Catamaran Corp. (NASDAQ:CTRX; TSX:CCT), Schaumburg, Ill. Cigna Corp. (NYSE:CI), Bloomfield, Conn. Business: Infectious Catamaran selected Gileads Harvoni …

    Published on 2/9/2015
  • AbbVie sales and marketing update

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Infectious Missouris Medicaid agency said it will make AbbVies Viekira Pak its preferred regimen to treat HCV infection in exchange for undisclosed rebates. Missouri is …

    Published on 2/2/2015
  • Boehringer Ingelheim sales and marketing update

    Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Pulmonary Boehringer launched Spiriva Respimat tiotropium bromide inhalation spray in the U.S. to treat bronchospasm associated with chronic obstructive pulmonary …

    Published on 2/2/2015
  • Gilead, Envision Pharmaceutical Holdings LLC, UnitedHealth Group sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Envision Pharmaceutical Holdings LLC, Twinsburg, Ohio UnitedHealth Group Inc. (NYSE:UNH), Minneapolis, Minn. Business: Infectious UnitedHealth selected Gileads …

    Published on 2/2/2015
  • GlaxoSmithKline sales and marketing update

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Business: Inflammation, Pulmonary GlaxoSmithKline launched two drugs in the U.S.: Arnuity Ellipta fluticasone furoate inhalation powder to treat asthma; and Incruse …

    Published on 2/2/2015
  • Lupin sales and marketing update

    Lupin Ltd. (NSE:LUPIN; BSE:500257), Mumbai, India Business: Neurology Lupins Lupin Pharmaceuticals Inc. subsidiary launched an authorized generic of pain drug Celebrex celecoxib in the U.S. in 50, 100, 200 and 400 mg …

    Published on 2/2/2015
  • Purdue Pharma sales and marketing update

    Purdue Pharma L.P., Stamford, Conn. Business: Neurology Purdue launched Hysingla ER in the U.S. to manage long-term severe pain. Hysingla is a once-daily, extended-release (ER) formulation of hydrocodone bitartrate …

    Published on 2/2/2015
  • Takeda Pharmaceuticals Co. Ltd. sales and marketing update

    Takeda Pharmaceuticals Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Other Takeda launched IV fomepizole in Japan to treat ethylene glycol and methanol poisoning. Takeda has exclusive, Japanese rights to develop and …

    Published on 2/2/2015
  • AbbVie sales and marketing update

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Infectious AbbVie entered an agreement with the ADAP Crisis Task Force (ACTF) to provide its HCV regimen Viekira Pak at an undisclosed discount to state AIDS Drug …

    Published on 1/26/2015
  • Gilead, Aetna sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Aetna Inc. (NYSE:AET), Hartford, Conn. Business: Infectious Aetna has selected Gileads Harvoni ledipasvir/sofosbuvir to treat HCV genotype 1 infection and Sovaldi …

    Published on 1/26/2015
  • Merck sales and marketing update

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Infectious FDA said Victrelis boceprevir from Merck for HCV genotype 1 infection will be discontinued. The small molecule HCV NS3/4A protease inhibitor …

    Published on 1/26/2015
  • AbbVie, Gilead, Harvard Pilgrim Health Care Inc., Humana, Prime Therapeutics LLC sales and marketing update

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Harvard Pilgrim Health Care Inc., Wellesley, Mass. Humana Inc. (NYSE:HUM), Louisville, Ky. Prime Therapeutics LLC, St. Paul,…

    Published on 1/19/2015
  • Abbott sales and marketing update

    Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Business: Infectious Abbott launched Iridica in Europe and other countries that recognize CE Mark approval to identify pathogens causing infections. Iridica can identify…

    Published on 1/12/2015
  • Amarantus BioScience sales and marketing update

    Amarantus BioScience Holdings Inc. (OTCQB:AMBS), San Francisco, Calif. Business: Diagnostic Amarantus launched blood diagnostic LymPro to detect Alzheimers disease (AD). The diagnostic is only available for …

    Published on 1/12/2015
  • Endo sales and marketing update

    Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland Business: Infectious, Generics Endo launched a generic version of Valcyte valganciclovir from Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) in the U.S. …

    Published on 1/12/2015
  • Gilead, Anthem, CVS Health sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Anthem Inc. (NYSE:ANTM), Indianapolis, Ind. CVS Health Corp. (NYSE:CVS), Woonsocket, R.I. Business: Infectious CVS Health announced that it would give exclusive …

    Published on 1/12/2015
  • Keryx sales and marketing update

    Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), New York, N.Y. Business: Renal Keryx launched Auryxia ferric citrate tablets in the U.S. to control serum phosphorus levels in patients with chronic kidney disease (CKD) on …

    Published on 1/12/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993